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Abstract
Background: Hypertrophic cardiomyopathy is a frequent manifestation in Fabry disease (FD) - an X-linked
lysosomal storage disorder caused by reduced activity of the enzyme a-galactosidase A. In FD an elevation of
specific cardiac biomarkers, such as cardiac troponin I (cTNI) has been reported in case of clinical manifestation
suggestive of myocardial ischemia. In diagnosing acute myocardial infarction cTNI is considered the most reliable
parameter.
Case Presentation: In the referred case we present a 59 years old female patient with the diagnosis of FD
presenting with persistently increased cTNI level (lowest value 0.46 ng/ml, highest value 0.69 ng/ml; normal range
<0.05 ng/ml) over a period of 5 months lacking cardiac clinical signs. Since renal insufficiency did not explain the
degree of cTNI elevation, this was interpreted as a result of cardiac involvement in FD. Cardiac MRI showed marked
left ventricular hypertrophy and focal late Gadolinium enhancement.
Conclusions: Our case report demonstrates a persistent cTNI release in FD with cardiac involvement. Proving the
persistence in a symptom free interval, it might be related to a direct damage of myocytes. In FD cTNI could serve
as a beneficial long term parameter providing new perspectives for screening strategies.
Background
Fabry disease (FD) is an X-linked lysosomal disorder
caused by reduced activity of the enzyme a-galactosi-
dase A, leading to excessive deposition of glycosphingo-
lipids in the vascular endothelium and tissues
throughout the body [1,2]. In the heart, glycosphingoli-
pids deposition causes progressive left ventricular hyper-
trophy that mimics the morphological and clinical
characteristics of hypertrophic cardiomyopathy [1,3]. In
FD an elevation of specific cardiac biomarkers, such as
cardiac troponin I (cTNI) has been reported in case of
clinical manifestation suggestive of myocardial ischemia
[4-6]. In diagnosing acute myocardial infarction cTNI is
considered the most reliable parameter [7,8]. However,
in different disorders a cTNI elevation could be
observed without any obvious cardiac involvement and
even without clinical sings [9-15]. It is so far unknown
whether increased cTNI levels in FD occur in clinically
silent intervals. Long term profiles of cTNI in FD
patients with cardiac involvement have not yet been
reported.
We report on a patient with cardiac involvement in FD
presenting with persistently elevated cTNI over a period
of 5 months, lacking of cardiac clinical manifestations.
Case Presentation
In a 57 years old female patient a screening for FD has
been carried out due to painful neuropathy. A genetic
analysis confirmed the diagnosis of FD (c.424T > C,
[C142R]) [16]. An extensive subsequent work-up
revealed an advanced organ manifestation including the
eyes, kidneys, peripheral and central nervous system and
the heart. Consequently an enzyme replacement therapy
(ERT) was established.
Two years after the onset of ERT, the patient
described an episode of dyspnea during physical activity.
The symptoms resolved at rest. A subsequent cTNI
assessment revealed a value of 0.46 ng/ml (normal range
<0.05 ng/ml). The patient was hospitalised and treated
b a s e do nt h er e g i m e no na na c u t ec o r o n a r ys y n d r o m e .
The actual coronary angiography revealed regular
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remarkable left ventricular hypertrophy. Furthermore a
late Gadolinium enhancement imaging indicated a focal
parenchymal fibrosis, which is a common finding in FD
patients with cardiac involvement (Figure 2). In line
with findings depicted in the coronary angiography the
electrocardiogram (ECG) did not show typical changes
suggestive to an acute myocardial ischemia. A sinus
rhythm (78/minutes), a normal cardiac axis and no
pathological intervals were observed. The single obvious
abnormality was an ST segment depression with a pre-
terminal negative T wave in the leads I, II, aVL, aVF
and V3-V6. In comparison, the ECG performed one year
prior to the actual event revealed similar findings. On
exercise ECG no cardiac symptoms occurred whereas
the ECG morphology remained unchanged. The Holter
ECG showed no relevant arrhythmias. Transthoracic
echocardiography revealed left ventricular hypertrophy
Figure 1 Coronary angiography ruling out relevant coronary artery disease. Left coronary artery: a left anterior oblique projection with
caudal (A) and cranial (B) angulation and a right anterior oblique projection with cranial (C) angulation. (D): right anterior oblique projection of
the right coronary artery.
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ciencies. On discharge a cTNI value of 0.67 ng/ml was
measured. A therapy with aspirin 100 mg daily was
established.
Apart from slight palpitations after intensive exercise
during the following 4 weeks, no further relevant car-
diac symptoms occurred. The hospitalisation did not
lead to an interruption of the enzyme replacement
therapy. Over a period of 5 months the cTNI value
was assessed at least twice monthly. Apart from slight
fluctuations, the cTNI remained increased over this
period (Figure 3). The ECG performed two months
thereafter revealed findings consistent with previous
examinations; in particular no inferior Q waves were
evident in the subsequent ECG. A relevant deteriora-
tion of the renal function could not be observed fol-
lowing the diagnosis of FD, thus a significant renal
insufficiency responsible for the elevated cTNI could
Figure 2 Cardiac MRI showing a marked hypertrophic cardiomyopathy. Balanced Fast Field Echo (bFFE) cine sequence, short axis view (A);
4 chamber view (B); a left ventricular hypertrophy with normal contractility was recognized. T1 weighted black blood Turbo spin echo sequence,
short axis view (C); left ventricular hypertrophy is evident, specifically in the septal region. Corresponding view with transmural late Gadolinium
enhancement (arrow) in the lateral wall using a T1 weighted inversion recovery 3D fast gradient echo sequence (D).
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glomerular filtration rate (GFR) was 37.3 ml/min, the
current measurement revealed a value of 53.4 ml/min
(both values measured per 24-h urine/1.73 body sur-
face area). The serum creatinine level did not exceed
1.1 mg/dl. As there was no evidence for an acute myo-
cardial ischemia explaining the cTNI increase, the
measurements of cTNI in short intervals was ceased.
Discussion
The main finding in the present case is a persistent
cTNI elevation in a FD patient with cardiac involve-
ment. Left ventricular hypertrophy, which was evident
in our patient, is one of the most frequent pathological
cardiac finding in FD. In case of cardiac clinical mani-
festation it might result in cTNI elevation [4]. In con-
trast, the presented case demonstrates a persistence of
increased cTNI level, even in symptom free intervals.
Since cTNI is considered highly specific for myocar-
dial damage, usually prompting further cardiological
investigation, including invasive methods such as a cor-
onary angiography, our observation is of high clinical
relevance [7,8]. As small vessel ischemic disease is the
suspected cause of the myocardial damage in FD, a per-
sistent elevation of cardiac biomarkers implicates a con-
tinuous silent ischemia [4]. Proving a persistent cTNI
elevation in a symptom free interval, increased cTNI
levels could be interpreted as a direct damage of myo-
cytes due to the deposition of glycosphingolipids. Even
though the latter mechanism appears likelier, the patho-
mechanism behind our observation requires further
assessment. A cTNI elevation as a simple coincidental
independent finding seams unlikely facing the marked
cardiac changes in our patient. In case of evidence of a
direct relationship between the cTNI elevation and
degree of the cardiac damage in FD, a cTNI measure-
ment would be of great value as a marker for the severity
of cardiac involvement. It could also serve for long term
monitoring in patients on ERT. Further investigations are
therefore promptly needed to enable a better understand-
ing of cTNI release and cardiac involvement in FD with
important implications for the care of these patients.
Renal insufficiency, which is also a frequent manifesta-
tion in FD, needs to be taken into consideration when
interpreting elevated cTNI values [17,18]. As demon-
strated by Flisinski et al. in patients with chronic kidney
disease who were treated with haemodialysis, cTNI
values of 0.017 - 0.143 ng/ml occurred without any
signs of acute myocardial damage; in patients with a
GFR of < 53 ml/min cTNI levels did not exceed 0.23
ng/ml (99th percentile) [17]. In this context the reduced
GFR in our patient might be of some relevance, however
the increased values of 0.69 ng/ml can not solely be
caused by renal insufficiency.
Elevation of cardiac biomarkers in the absence of an
a c u t ec o r o n a r ys y n d r o m eh a sd r a w nm o r ea n dm o r e
attention over the past years, indicating numerous con-
ditions associated with cTNI release of unknown origin
[9-15]. The evidence of a persistent and clinically silent
cTNI elevation in FD would subsequently raise the
question of the relevance of FD among patients with a
cTNI release of unknown origin. Elevated cTNI levels
might be of particular interest in patients with unclear
renal insufficiency with respect to the diagnostic value
in identifying patients with FD. In a high percentage of
patients with FD renal and cardiac involvement are con-
comitant findings [19,20]. A possible consequence could
be the implementation of cTNI assessment in the renal
diagnostic algorithm for proving a cardiomyopathy,
which potentially indicates involvement of FD. This
would be of great value for an early detection of FD,
prompting access to treatment in forms of ERT for this
disease.
Conclusions
In conclusion, our case report demonstrates a persistent
cTNI release in the absence of clinical signs in a patient
with cardiac involvement in FD. A further evaluation of
cTNI in patients with FD appears mandatory, presum-
ably serving as a beneficial long term parameter and
providing new perspectives for screening strategies.
Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompany-
ing images.
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Figure 3 Cardiac troponin I levels in ng/ml (highest and lowest
values) within 5 months.
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